B+
Bull case
25%
Probability
Target price
$9.25
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
INNV
InnovAgeFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The post-earnings bull read is that Q3 showed another step-up in execution: revenue grew 15.5%, Adjusted EBITDA nearly tripled year over year to $30.5 million, guidance was raised again, and cash generation improved. The immediate earnings reaction was positive, with after-hours coverage pointing to investors focusing on the beat/raise rather than the GAAP loss.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
Growth still depends on filling existing centers, maturing newer Florida locations, and maintaining lower cost per participant; if utilization, pharmacy, or staffing trends reverse, recent margin gains could fade [#8-K-2026-05-05].
Momentum
19
Value
51
Sentiment
33
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.25 · Bull $9.25 · Bear $5.75Analysis 2026-05-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $12.00
Why
Momentum19 · Δ7d -0.5
Value51 · Δ7d -0.2
Sentiment33 · Δ7d -5.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.2.
Contradictions & invalidation
- • Growth still depends on filling existing centers, maturing newer Florida locations, and maintaining lower cost per participant; if utilization, pharmacy, or staffing trends reverse, recent margin gains could fade [#8-K-2026-05-05].
- • InnovAge remains exposed to government-payor concentration, reimbursement resets, audits, and compliance scrutiny inherent in the PACE model, all of which are explicit risk factors in company disclosures [#10-K-2025-09-09].
- • The bear read is that GAAP profitability deteriorated because corporate G&A was hit by litigation liability, and management used the same earnings follow-up to warn that FY2027 rate growth could be more tempered.
Catalyst clock
2026-06-30
Cash build and operating cash flow reduce immediate financing pressure
Lead driver: Value · See fundamentals
Momentum
19
8% active weight
Current posture
7d trendFlat
Δ7d
-0.5
Δ21d
-11.4
Value
51
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.4
Sentiment
33
45% active weight
Current posture
7d trendSoftening
Δ7d
-5.4
Δ21d
-11.5
Why this grade
Composite grade F. Momentum 18.9 / Value 50.7 / Sentiment 33.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-08. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$7.25
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$5.75
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$1.3B
Beta
0.56
Shares Out
136.45M
P/E (TTM) · Derived
-510.7
P/S (TTM)
0.84
P/FCF (TTM)
20.61
Rev YoY
+15.5%
EPS YoY
+157.8%
Gross Margin
+19.8%
Op Margin
+0.6%
Net Debt
-$4.83M
Current Ratio
1.03
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data